Dementia is already affecting millions worldwide. In 2019, 10.3 million new cases were reported globally, and the lifetime risk at older ages is about 1 in 3 people. The burden is uneven, with prevalence about 2.5 times higher in low-income settings than in high-income settings.
Key Takeaways
- 10.3 million new cases of dementia occurred worldwide in 2019 (global incidence)
- In 2019, dementia accounted for 3.2% of global deaths among people aged 70+
- 2.5x higher prevalence of dementia in low-income settings than high-income settings among older adults (age-standardized prevalence ratio)
- WHO estimates dementia affects 1 in 3 people across the world during their life expectancy at older ages (lifetime risk statement in fact sheet)
- In 2022, there were 15 million family caregivers of people with Alzheimer’s disease or other dementias in the US
- In a 2022 review, telehealth interventions reduced caregiver burden by an average standardized mean difference of ~0.5 (meta-analysis effect size)
- $2,000 annual direct non-medical out-of-pocket spending per Medicare beneficiary with Alzheimer’s in the US (average annual)
- In the US, caregiver time associated with dementia was valued at $2.5 trillion in 2018 (economic value of informal care)
- In 2019, healthcare costs were 57% of dementia costs in Europe, while social care and informal care made up the remainder (proportional breakdown)
- Average time from symptom onset to diagnosis for dementia is about 2 years (median delay estimate from published reviews)
- Only 36% of people with dementia report receiving a diagnosis during life in a global systematic review (diagnosed proportion)
- In the US, Medicare spending for beneficiaries diagnosed with Alzheimer’s/dementia began to increase 5 years before formal diagnosis (pre-diagnosis utilization)
- The global dementia drug pipeline had 149 programs in development as of 2023 (count of active dementia drug pipeline programs)
- There were 122 dementia-related clinical trials active in 2023 worldwide (ClinicalTrials.gov snapshot count)
- Lecanemab (Leqembi) had a reduction in amyloid-related imaging abnormalities (ARIA) rates that were quantified in the CLARITY-AD trial publication
In 2019, dementia affected 55 million globally, costing trillions and demanding major caregiver support worldwide.
Related reading
01 · Category
Prevalence & Burden3 stats
01
10.3 million new cases of dementia occurred worldwide in 2019 (global incidence)
02
In 2019, dementia accounted for 3.2% of global deaths among people aged 70+
03
2.5x higher prevalence of dementia in low-income settings than high-income settings among older adults (age-standardized prevalence ratio)
Interpretation
Prevalence & Burden Interpretation
In 2019, dementia hit the global population hard with 10.3 million new cases worldwide and it contributed to 3.2% of deaths among people aged 70+, while prevalence was 2.5 times higher in low-income than high-income settings, underscoring a major and unequal burden within the Prevalence and Burden category.
02 · Category
Industry & Delivery Trends7 stats
01
WHO estimates dementia affects 1 in 3 people across the world during their life expectancy at older ages (lifetime risk statement in fact sheet)
02
In 2022, there were 15 million family caregivers of people with Alzheimer’s disease or other dementias in the US
03
In a 2022 review, telehealth interventions reduced caregiver burden by an average standardized mean difference of ~0.5 (meta-analysis effect size)
04
In a randomized trial, digital cognitive stimulation improved MMSE by about 1 point over control after 12 weeks (reported outcome)
05
In the US, the National Plan to Address Alzheimer’s requires 2025 milestones; one quantified goal is increasing diagnosis and care (program metrics)
06
In Europe, average waiting time for dementia specialist assessment was reported as 6.9 weeks in a cross-country survey (delivery metric)
07
In a UK study, 28% of people with dementia had at least one unplanned hospital admission in 12 months
Interpretation
Industry & Delivery Trends Interpretation
Delivery and industry efforts are being pressured to scale faster because even as telehealth can cut caregiver burden by about a standardized mean difference of 0.5 and digital cognitive stimulation can raise MMSE by roughly 1 point in 12 weeks, major gaps remain with Europe reporting a 6.9 week average wait for specialist assessment and the UK seeing 28% of people with dementia experience an unplanned hospital admission within 12 months.
03 · Category
Cost Analysis5 stats
01
$2,000annual direct non-medical out-of-pocket spending per Medicare beneficiary with Alzheimer’s in the US (average annual)
02
In the US, caregiver time associated with dementia was valued at $2.5 trillion in 2018 (economic value of informal care)
03
In 2019, healthcare costs were 57% of dementia costs in Europe, while social care and informal care made up the remainder (proportional breakdown)
04
In 2019, the average annual cost per dementia patient in the US ranged from $7,000to $38,000 depending on setting (annual direct costs)
05
Global cost of dementia was estimated at about US$1.3 trillion in 2019
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, dementia imposed a global price tag of about US$1.3 trillion in 2019, with US annual direct costs per patient ranging from roughly $7,000 to $38,000 and caregiver time alone valued at $2.5 trillion in 2018, showing that the financial burden extends far beyond medical spending.
More related reading
04 · Category
Diagnosis & Care8 stats
01
Average time from symptom onset to diagnosis for dementia is about 2 years (median delay estimate from published reviews)
02
Only 36% of people with dementia report receiving a diagnosis during life in a global systematic review (diagnosed proportion)
03
In the US, Medicare spending for beneficiaries diagnosed with Alzheimer’s/dementia began to increase 5 years before formal diagnosis (pre-diagnosis utilization)
04
In a US claims study, 44% of dementia patients had at least one potentially preventable emergency department visit in the year after diagnosis
05
In a systematic review, caregivers provided assistance for 4.5 hours/day on average for dementia patients (care time estimate)
06
In the UK, 1 in 6 people with dementia move into a care home within 1 year of diagnosis (care-home transition estimate)
07
In the US, 76% of people with Alzheimer’s disease receive care from a family caregiver (family caregiving share)
08
In a population-based study, 27% of people with dementia had comorbid diabetes (diabetes prevalence among dementia patients)
Interpretation
Diagnosis & Care Interpretation
From diagnosis to care, the numbers show that dementia is often identified late and followed by heavy support needs, with a median delay of about 2 years before diagnosis and only 36% of people diagnosed during life, while families provide most of the day to day help, averaging 4.5 hours per day for caregivers in systematic review estimates and 76% of Alzheimer’s care in the US coming from family caregivers.
05 · Category
Research & Pipeline7 stats
01
The global dementia drug pipeline had 149 programs in development as of 2023 (count of active dementia drug pipeline programs)
02
There were 122 dementia-related clinical trials active in 2023 worldwide (ClinicalTrials.gov snapshot count)
03
Lecanemab (Leqembi) had a reduction in amyloid-related imaging abnormalities (ARIA) rates that were quantified in the CLARITY-AD trial publication
04
In the CLARITY-AD trial, lecanemab reduced decline on the CDR-SB by 27% over 18 months in early Alzheimer’s disease
05
In the phase 3 TRAILBLAZER-ALZ 2 trial, donanemab reduced cognitive/functional decline by 40% on ADAS-Cog13 in amyloid-confirmed participants (as reported)
06
In the phase 3 NIA-AA registry analysis, 1 in 4 dementia cases were estimated to be attributable to potentially modifiable risk factors (fraction attributable from published studies)
07
Smoking (previous smoking) accounts for about 5.8% of dementia cases globally in the Lancet Commission estimates
Interpretation
Research & Pipeline Interpretation
In the Research and Pipeline landscape, dementia prevention and treatment momentum is evident with 149 active drug programs and 122 ongoing global clinical trials in 2023, alongside trial results showing meaningful disease slowing such as lecanemab’s 27% reduction in CDR-SB decline over 18 months and donanemab’s 40% improvement on ADAS-Cog13, while modifiable risk factors are estimated to drive about 25% of dementia cases.
report visual · Comparison
Dementia’s global burden and impact (selected estimates)
In 2019, dementia generated 10.3M new cases worldwide and accounted for 3.2% of global deaths among people aged 70+. Lifetime risk is estimated at about 1 in 3 people.
New dementia cases worldwide (2019, global incidence)10.3
Share of global deaths among ages 70+ (2019)3.2%
Lifetime risk at older ages (WHO estimate)3
Global cost of dementia (2019)$1.3
source-verifiedthelancet.com · who.int · ncbi.nlm.nih.gov2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Dementia Statistics. Gitnux. https://gitnux.org/dementia-statistics
MLA
Helena Kowalczyk. "Dementia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dementia-statistics.
Chicago
Helena Kowalczyk. 2026. "Dementia Statistics." Gitnux. https://gitnux.org/dementia-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)